NCT02037763

Brief Summary

This is a prospective observational cohort multinational clinical study. There are no biomarkers to help predict in which patients acute low back pain (LBP) will transform into chronic low back pain (CLBP). Human variability and different common comorbidities complicate the picture and make stratification of patients into correct subgroups difficult. However, drugs act by targeting specific molecular pathways and are therefore efficient only in a subgroup of patients sharing common molecular pathology and common genetics. Both CLBP and disc degeneration are known to be heritable. Little investigation has taken place for genetic variants in CLBP. The main aim of this trial is to identify "omics biomarkers" associated with the transition from acute (single episode of low back pain) to persistent/chronic LBP (pain lasting more than 12 weeks).

Trial Health

50
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
5,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Dec 2014

Typical duration for all trials

Geographic Reach
6 countries

7 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 14, 2014

Completed
2 days until next milestone

First Posted

Study publicly available on registry

January 16, 2014

Completed
11 months until next milestone

Study Start

First participant enrolled

December 1, 2014

Completed
3.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2018

Completed
Last Updated

September 26, 2016

Status Verified

September 1, 2016

Enrollment Period

3.7 years

First QC Date

January 14, 2014

Last Update Submit

September 22, 2016

Conditions

Keywords

Low back painGWASGlycomicsActivomicsEpigenetics

Outcome Measures

Primary Outcomes (1)

  • Genetic outcome

    To investigate the associations between genetic factors and the development of persistent chronic LBP, in patients developing persistent chronic symptoms (defined as pain that persists 3 months or more), after an episode of acute LBP. The development of persistent chronic pain will be assessed at 3 months after the acute episode. Existing and newly generated GWAs will be analyzed and their possible correlation with the risk of pain becoming persistent chronic will be detected in a wide, international population of caucasian ancestry.

    54 months

Secondary Outcomes (6)

  • Glycomic and Activomic outcome

    54 months

  • Epigenetic outcome

    54 months

  • Next-generation sequencing outcome

    54 months

  • Stratification based on pain characteristics

    54 months

  • Stratification based on pain pathophysiology

    54 months

  • +1 more secondary outcomes

Eligibility Criteria

Age18 Years - 99 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Each clinical centre will identify patients with an episode of acute LBP, with or without irradiation, referred from primary care physicians, orthopaedic specialists or directly selected in the emergency room (accessing hospital for acute low back pain). The enrolment will be competitive among the participating clinical centres.

You may qualify if:

  • age: older than 18;
  • acute episode of pain between the costal margins and gluteal fold, with or without symptoms into one or both legs lasting less than 6 weeks;
  • written informed consent signed;
  • Caucasian ancestry

You may not qualify if:

  • evidence of clinically unstable disease;
  • severe psychiatric disorder (excluding mild depression) or mental impairment;
  • history (in the last 6 months) of persistent chronic low back pain or acute LBP episodes
  • recent history (\< 1 year) of spinal fracture;
  • pain in the back due to spinal tumor or infection;
  • pregnancy;

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (7)

The Center for Clinical Research (CPI)

Winston-Salem, North Carolina, United States

RECRUITING

Edith Cowan University (ECU)

Perth, Australia

RECRUITING

Multidisciplinary Pain Centre, Hospital Oost-Limburg (ZOL)

Genk, Belgium

RECRUITING

"St.Catharine" Orthopedics, Surgery, Neurology and Physical Medicine and Rehabilitation Specialty Hospital (St-Cat)

Zabok, Croatia

RECRUITING

Anesthesia and Pain Therapy Department, Università degli Studi di Parma (UNIPR)

Parma, Italy

RECRUITING

Fondazione IRCCS Policlinico San Matteo (OSM)

Pavia, 27100, Italy

RECRUITING

King's College London (KCL)

London, United Kingdom

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

Whole blood samples will be collected at recruitment in all enrolled patients. Blood samples will be collected also at the 3 months and 6 months follow up visits in patients who will develop CLBP after the episode of acute LBP.

MeSH Terms

Conditions

Low Back Pain

Condition Hierarchy (Ancestors)

Back PainPainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • MASSIMO ALLEGRI, MD

    Pain Therapy Service Azienda Ospedaliera Universitaria Parma Italy

    PRINCIPAL INVESTIGATOR

Central Study Contacts

MASSIMO ALLEGRI, MD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD

Study Record Dates

First Submitted

January 14, 2014

First Posted

January 16, 2014

Study Start

December 1, 2014

Primary Completion

August 1, 2018

Study Completion

August 1, 2018

Last Updated

September 26, 2016

Record last verified: 2016-09

Locations